Interestingly, a subgroup analyses of the recently published KEYNOTE-811 study which demonstrated an additive effect of pembrolizumab to trastuzumab-chemotherapy (27), in treatment naïve advanced HER2 positive GEACs with a PD-L1 combined positive score (CPS)>1, showed that this effect was more pronounced in tumors with a location in the stomach (HR 0.7) compared to tumor in the GEJ (HR 0.85). The gene discussed is ERBB2; the disease is neoplasm.